Gene Transduction of Natural Killer Cells for Clinical Application
- 29 March 2022
- book chapter
- Published by Springer Nature
- Vol. 2463, 311-328
Abstract
Autologous T cells expressing chimeric antigen receptor (CAR) have produced a spectacular response in hematological malignancies. This success of cellular therapy has inspired the exploration of the therapeutic potential of other immune cell types. In this regard, natural killer (NK) cells hold great potential as they can identify tumor cells by mechanisms that are different from those used by T cells and have a high cytotoxic capacity. Their capacity to recognize tumors and killing potency can be further enhanced by genetic modification. Our laboratory has developed a clinically adaptable method to manufacture genetically modified NK cells using retroviral vectors in compliance with current good manufacturing practice regulations. Here, we describe relevant technical procedures, including isolation of peripheral blood mononucleated cells from a leukapheresis product, T-cell depletion, stimulation and transduction of NK cells, and preparation of transduced NK cells for infusion.Keywords
This publication has 28 references indexed in Scilit:
- T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell KillingCancer Research, 2014
- A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor CellsCancer Research, 2013
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignanciesCytotherapy, 2012
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor modelBlood, 2009
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell TherapyCancer Research, 2009
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cellsCytotherapy, 2009
- Monoclonal antibody therapy of cancerNature Biotechnology, 2005
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cellsExperimental Hematology, 2004
- Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in childrenBone Marrow Transplantation, 1999